Loading...
 

Volume 27, Issue 2, June 2016

Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2016; 27(2): 67-70
A multicenter prospective registry of patients with Antiphosholipid Syndrome in Greece (The Greek APS registry)
Authors Information

Rheumatology Unit

First Department of Propaeudeutic and Internal Medicine, Joint Rheumatology Program School of Medicine, National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece
Abstract
Antiphospholipid syndrome (APS) is a hypercoagulable state characterized by vascular thromboses, pregnancy morbidity and the presence of antiphospholipid antibodies (aPL), namely lupus anticoagulant, anticardiolipin antibodies and anti-beta 2 glycoprotein I (anti-β2GPI) antibodies. APS can clinically present with arterial and venous thrombotic manifestations and/or pregnancy morbidity as well as various non-classical manifestations such as heart valve abnormalities, thrombotic renal microangiopathy, skin involvement and thrombocytopenia. A small percentage (<1%) of patients with APS develop systemic, multiorgan life-threatening complications defined as catastrophic APS. Treatment mainly consists of anticoagulant and/or antiplatelet agents. The aim of the current project is to create a Greek Registry of consecutive patients with APS followed regularly in university centers with detailed recording of demographic, disease-related serological and clinical parameters, prevalence of comorbidities including traditional risk factors for thrombosis, infections and neoplasms, and the current and previous use of different antithrombotic or anti-inflammatory regimens.